Slayback Pharma Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
85
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
4
Slayback Pharma General Information
Description
Manufacturer of pharmaceutical products focused on complex injectables and other non-solid oral products. The company engages in the research and development of complex, generics, and specialty pharmaceutical drugs and offers smart product selection and execution, enabling clients to develop drugs using rapid development capabilities and delivery technologies.
Contact Information
Website
www.slayback-pharma.comCorporate Office
- 301 Carnegie Center
- Suite 303
- Princeton, NJ 08540
- United States
Corporate Office
- 301 Carnegie Center
- Suite 303
- Princeton, NJ 08540
- United States
Slayback Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Slayback Pharma Comparisons
Industry
Financing
Details
Slayback Pharma Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tris Pharma | Private Debt Financed | Monmouth Junction, NJ | ||||
| Beloteca | Corporation | San Diego, CA | ||||
| IriSys (Pharmaceuticals) | Formerly VC-backed | San Diego, CA | ||||
| Eagle Pharmaceuticals | Formerly VC-backed | Woodcliff Lake, NJ | ||||
| Durect | Formerly VC-backed | Cupertino, CA |
Slayback Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Slayback Pharma Patents
Slayback Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240285582-A1 | Stable pharmaceutical compositions of edaravone | Pending | 16-Feb-2023 | ||
| US-20240156829-A1 | Stable antiemetic emulsions for parenteral administration | Pending | 31-Oct-2022 | ||
| US-20240050416-A1 | Stable pharmaceutical compositions of apixaban | Inactive | 27-Jul-2022 | ||
| US-20240197705-A1 | Stable pharmaceutical compositions of apixaban | Pending | 27-Jul-2022 | ||
| US-20230381282-A1 | Stable liquid compositions of glucagon | Pending | 26-May-2022 | A61K38/26 |
Slayback Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Slayback Pharma Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Slayback Pharma FAQs
-
When was Slayback Pharma founded?
Slayback Pharma was founded in 2011.
-
Who is the founder of Slayback Pharma?
Ajay Singh is the founder of Slayback Pharma.
-
Where is Slayback Pharma headquartered?
Slayback Pharma is headquartered in Princeton, NJ.
-
What is the size of Slayback Pharma?
Slayback Pharma has 85 total employees.
-
What industry is Slayback Pharma in?
Slayback Pharma’s primary industry is Drug Discovery.
-
Is Slayback Pharma a private or public company?
Slayback Pharma is a Private company.
-
What is Slayback Pharma’s current revenue?
The current revenue for Slayback Pharma is .
-
How much funding has Slayback Pharma raised over time?
Slayback Pharma has raised $138M.
-
Who are Slayback Pharma’s investors?
Everstone Capital and Kohlberg Kravis Roberts have invested in Slayback Pharma.
-
Who are Slayback Pharma’s competitors?
Tris Pharma, Beloteca, IriSys (Pharmaceuticals), Eagle Pharmaceuticals, and Durect are some of the 17 competitors of Slayback Pharma.
-
When was Slayback Pharma acquired?
Slayback Pharma was acquired on 27-Sep-2023.
-
Who acquired Slayback Pharma?
Slayback Pharma was acquired by Azurity Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
